Clinical Trial Update: Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating avatrombopag for primary prevention of cytarabine-induced thrombocytopenia in lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Thrombocytopenia

Drugs mentioned

• Avatrombopag (avatrombopag)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use | Phase 2 | Status: UNKNOWN